Physician profile
Ginger Nichole Locklear
NPI 1265750194
$1,439.83
in general payments reported to CMS, 2019-2025
16 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $114 · 2021: $241 · 2022: $227 · 2023: $233 · 2024: $346 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $749.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $315.34 | 2019-2024 | Jornay Pm |
| Corium, LLC | $206.91 | 2023-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $197.31 | 2020-2022 | |
| Aytu Biopharma, INC. | $162.06 | 2020-2025 | Karbinal |
| Tris Pharma INC | $104.85 | 2020-2024 | Onyda Xr |
| Supernus Pharmaceuticals, INC. | $103.15 | 2023-2025 | Qelbree, Qelbree |
| Alk-Abello, INC | $62.99 | 2023-2024 | Grastek, Ragwitek, Odactra |
| Avion Pharmaceuticals | $60.53 | 2021-2022 | |
| Pfizer INC. | $49.89 | 2021-2024 | |
| Glaxosmithkline, LLC. | $44.33 | 2022-2024 | Bexsero, Pediarix |
| Ars Pharmaceuticals Operations, INC. | $41.12 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $29.74 | 2024 | |
| Organon LLC | $19.58 | 2024 | |
| Collegium Pharmaceutical, INC. | $14.55 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $14.03 | 2023 | Cotempla Xr-Odt |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $13.45 | 2023 | Flumist Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ginger Locklear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.